ABBV · News · 20261114N
Licensing / Collaboration Deals
AbbVie Inc. · 2026-11-14 · Importance null · Surprise null
AbbVie’s partner Brise Pharmaceuticals reported progress on two preclinical migraine programs under an exclusive license agreement. The programs met several near-term milestones, while AbbVie retains global development and commercial control and Brise bears the early-stage risk. The report did not specify milestone payments, financial impact, or a timeframe for development or commercialization.
Key facts
- AbbVie’s exclusive license deal with Brise Pharmaceuticals uses outsourced discovery, with Brise bearing the early-stage risk while AbbVie retains global development and commercial control. source